Novartis psoriasis drugs secukinumab than Amgen's Enbrel in the latter study, the Swiss company said on Monday, put it in a clutch of new treatment methods to gain market recognition, becoming the first line.
Involving 1,307 patients in Phase III trials showed, secukinumab Enbrel is more effective than the removal of the skin with moderate to severe plaque psoriasis, itching and scaling of painful and unsightly skin condition that causes disease.
Novartis said it expects full findings will be presented later in the year and on track for regulatory approval by the end of the file, it is.
, Head of Global Development at Novartis Tim Wright, said: "These results show, secukinumab superior to Enbrel, the current standard of care treatment of moderate to severe plaque psoriasis life, it is good news."
Psoriasis is considered to be caused by the body's immune system to initiate the inflammatory response, and affects about 125 million people. Those suffering from diabetes and heart disease are also at greater risk of disease.
Novartis Pharma AG to develop new treatments for psoriasis, including AstraZeneca, Eli Lilly, Celgene Corporation and Amgen was one of the pack.
Citigroup analysts expect the flood of new therapeutic methods to help in the psoriasis market sales more than doubled to $ 7.6 billion by 2022, from $ 360 million in 2012 dollars.
Kepler Chevreux analysts predict peak sales $ 701 million, in 2020.
Novartis shares trading at nearly 1.5% at 68.60 Swiss francs ($ 71.18) for 1240 GMT, against the European healthcare index rose 1%.
 



Other News:
Novartis psoriasis drug superior to Enbrel in study
Greek municipal workers strike for 2nd day
S&P downgrades SoftBank to 'junk' status, shares slide
German exports fall at steepest rate since December 2009
Mexican border, mayoral, state vote raises tempers
Greek municipal workers strike for 2nd day
Facebook pushes search feature to more users
Former Mexican president Fox urges marijuana legalization